It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
HAE’s FA Score shows that 0 FA rating(s) are green whileXRAY’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
HAE’s TA Score shows that 5 TA indicator(s) are bullish while XRAY’s TA Score has 5 bullish TA indicator(s).
HAE (@Medical Specialties) experienced а -5.86% price change this week, while XRAY (@Medical Specialties) price change was +4.31% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was +3.22%. For the same industry, the average monthly price growth was +0.99%, and the average quarterly price growth was -2.23%.
HAE is expected to report earnings on Feb 11, 2025.
XRAY is expected to report earnings on Feb 26, 2025.
Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
HAE | XRAY | HAE / XRAY | |
Capitalization | 4.34B | 6.69B | 65% |
EBITDA | 264M | 249M | 106% |
Gain YTD | -0.094 | -46.710 | 0% |
P/E Ratio | 34.47 | 19.23 | 179% |
Revenue | 1.27B | 3.97B | 32% |
Total Cash | 194M | 334M | 58% |
Total Debt | 871M | 2.3B | 38% |
HAE | XRAY | ||
---|---|---|---|
OUTLOOK RATING 1..100 | 16 | 5 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 75 Overvalued | 4 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 58 | 93 | |
PRICE GROWTH RATING 1..100 | 46 | 65 | |
P/E GROWTH RATING 1..100 | 56 | 90 | |
SEASONALITY SCORE 1..100 | n/a | 75 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
XRAY's Valuation (4) in the Medical Specialties industry is significantly better than the same rating for HAE (75). This means that XRAY’s stock grew significantly faster than HAE’s over the last 12 months.
XRAY's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as HAE (100). This means that XRAY’s stock grew similarly to HAE’s over the last 12 months.
HAE's SMR Rating (58) in the Medical Specialties industry is somewhat better than the same rating for XRAY (93). This means that HAE’s stock grew somewhat faster than XRAY’s over the last 12 months.
HAE's Price Growth Rating (46) in the Medical Specialties industry is in the same range as XRAY (65). This means that HAE’s stock grew similarly to XRAY’s over the last 12 months.
HAE's P/E Growth Rating (56) in the Medical Specialties industry is somewhat better than the same rating for XRAY (90). This means that HAE’s stock grew somewhat faster than XRAY’s over the last 12 months.
HAE | XRAY | |
---|---|---|
RSI ODDS (%) | 2 days ago78% | 2 days ago50% |
Stochastic ODDS (%) | 2 days ago75% | 2 days ago57% |
Momentum ODDS (%) | 2 days ago64% | 2 days ago59% |
MACD ODDS (%) | 2 days ago66% | 2 days ago64% |
TrendWeek ODDS (%) | 2 days ago66% | 2 days ago62% |
TrendMonth ODDS (%) | 2 days ago65% | 2 days ago72% |
Advances ODDS (%) | 2 days ago66% | 4 days ago57% |
Declines ODDS (%) | 4 days ago63% | about 1 month ago69% |
BollingerBands ODDS (%) | 2 days ago77% | 2 days ago49% |
Aroon ODDS (%) | 2 days ago65% | 2 days ago80% |
A.I.dvisor indicates that over the last year, HAE has been loosely correlated with OM. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if HAE jumps, then OM could also see price increases.
A.I.dvisor indicates that over the last year, XRAY has been loosely correlated with KIDS. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if XRAY jumps, then KIDS could also see price increases.
Ticker / NAME | Correlation To XRAY | 1D Price Change % | ||
---|---|---|---|---|
XRAY | 100% | +0.65% | ||
KIDS - XRAY | 45% Loosely correlated | +3.80% | ||
HBIO - XRAY | 44% Loosely correlated | N/A | ||
STE - XRAY | 44% Loosely correlated | +1.66% | ||
ZBH - XRAY | 43% Loosely correlated | -0.80% | ||
NVST - XRAY | 43% Loosely correlated | +5.01% | ||
More |